Header

UZH-Logo

Maintenance Infos

Molekular zielgerichtete Therapie


Stenner-Liewen, F; Zippelius, A; Pestalozzi, B C; Knuth, A (2006). Molekular zielgerichtete Therapie. Der Chirurg, 77(12):1118-1125.

Abstract

Until recently, cancer therapy was based on three modalities: surgery, radiotherapy, and cytostatic chemotherapy. In most instances treatment of solid tumors was a surgical domain. For patients with incomplete resection or relapse after surgery, radiotherapy and chemotherapy usually offered only partial response and mostly of limited duration. By the mid-1990s visions of antibody-based therapies, vaccination strategies, and even gene-specific therapies existed but seemed far from clinical practice. United States Federal Drug Administration approval of the humanized antibody rituximab (1997) and the tyrosine kinase inhibitor imatinib (2001) has changed perceptions of oncologic treatment. These drugs turned visions into reality and led the pharmaceutical industry, clinicians, and patients to new perspectives. This article gives an overview of the development of this fourth modality in cancer therapy, so-called targeted therapy.

Abstract

Until recently, cancer therapy was based on three modalities: surgery, radiotherapy, and cytostatic chemotherapy. In most instances treatment of solid tumors was a surgical domain. For patients with incomplete resection or relapse after surgery, radiotherapy and chemotherapy usually offered only partial response and mostly of limited duration. By the mid-1990s visions of antibody-based therapies, vaccination strategies, and even gene-specific therapies existed but seemed far from clinical practice. United States Federal Drug Administration approval of the humanized antibody rituximab (1997) and the tyrosine kinase inhibitor imatinib (2001) has changed perceptions of oncologic treatment. These drugs turned visions into reality and led the pharmaceutical industry, clinicians, and patients to new perspectives. This article gives an overview of the development of this fourth modality in cancer therapy, so-called targeted therapy.

Statistics

Citations

Dimensions.ai Metrics
4 citations in Web of Science®
4 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

26 downloads since deposited on 19 Dec 2018
26 downloads since 12 months
Detailed statistics

Additional indexing

Other titles:Molecular targeted therapy
Item Type:Journal Article, refereed, original work
Communities & Collections:National licences > 142-005
Dewey Decimal Classification:610 Medicine & health
Language:German
Date:1 December 2006
Deposited On:19 Dec 2018 16:34
Last Modified:24 Sep 2019 23:46
Publisher:Springer
ISSN:0009-4722
OA Status:Green
Publisher DOI:https://doi.org/10.1007/s00104-006-1262-8
Related URLs:https://www.swissbib.ch/Search/Results?lookfor=nationallicencespringer101007s0010400612628 (Library Catalogue)
PubMed ID:17109101

Download

Download PDF  'Molekular zielgerichtete Therapie'.
Preview
Content: Published Version
Language: German
Filetype: PDF (Nationallizenz 142-005)
Size: 587kB
View at publisher